GlassScriptPhysician profile
Tiffany L Johnson
NPI 1033577457
$1,944.30
in general payments reported to CMS, 2019-2025
22 companies · $812 in 2025
The $812 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.84 · 2022: $188 · 2023: $573 · 2024: $296 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,680.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $793.30 | 2022-2025 | |
| Merz Pharmaceuticals, LLC | $242.04 | 2021-2024 | Xeomin |
| Microtransponder, INC. | $130.89 | 2023 | |
| Amneal Pharmaceuticals LLC | $105.86 | 2025 | Crexont |
| Nevro Corp. | $91.50 | 2022 | |
| Alexion Pharmaceuticals, INC. | $81.72 | 2025 | Ultomiris |
| Allergan, INC. | $56.50 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $49.94 | 2025 | |
| Inari Medical, INC. | $47.69 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Catalyst Pharmaceuticals, INC. | $39.59 | 2025 | |
| Neurelis, INC. | $38.03 | 2025 | Valtoco |
| Sk Life Science, INC. | $37.60 | 2025 | |
| Neurocrine Biosciences, INC. | $28.14 | 2025 | |
| Axsome Therapeutics, INC. | $25.64 | 2025 | Symbravo |
| Genzyme Corporation | $25.03 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $24.48 | 2025 | Vyvgart Hytrulo |
| Eisai INC. | $24.27 | 2025 | |
| Ucb, INC. | $23.86 | 2025 | Nayzilam |
| Tanabe Pharma America, INC. | $23.72 | 2025 | Radicava |
| Takeda Pharmaceuticals U.S.A., INC. | $22.67 | 2025 | Hyqvia |
| Teva Pharmaceuticals USA, INC. | $17.91 | 2025 | Austedo Xr |
| Amgen INC. | $13.92 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.